Adia Nutrition Inc. Introduces Cherry Payment Plans at Adia Med Clinics, Enhancing Access to Innovative Therapies
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/254843_20fd8c0b94a8a960_001full.jpg
The Cherry Payment Plans enable patients to spread treatment costs over manageable monthly installments, reducing financial barriers to accessing transformative therapies that can enhance their overall well-being. This initiative underscores Adia Nutrition's commitment to ensuring advanced treatments are within reach for those seeking to improve their personal vitality and appearance.
"Launching Cherry Payment Plans is a pivotal step toward making our therapies more inclusive," said Larry Powalisz, Chief Executive Officer of Adia Nutrition. "We believe every patient deserves access to innovative care, and these flexible payment options empower more individuals to experience the potential of treatments at Adia Med."
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/254843_20fd8c0b94a8a960_002full.jpg
Adia Med of Winter Park, which opened in January 2025, is part of a rapidly expanding clinical network dedicated to personalized care. Patients can explore Cherry Payment Plans to enhance affordability. Those interested in treatment options or financing are encouraged to fill out the contact form at www.adiamed.com.
For questions, inquiries, or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
A quick reminder: Adia Nutrition Inc. is presenting live today, June 11th, at 2:00 PM EST at the Life Sciences Virtual Investor Forum, hosted by VirtualInvestorConferences.com.
About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.comWebsite: www.adiamed.com Website: www.adialabs.comWebsite: www.biolete.comWebsite: www.cementfactory.coTwitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254843
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 hours ago
- Business Wire
FUTR Surpasses 1,000,000 Transactions and USD$380 Million in Payments Volume With FinWise Bank
TORONTO--(BUSINESS WIRE)--The FUTR Corporation (TSXV: FTRC) (OTCQB: FTRCF) ("FUTR" or the "Company"), a consumer-centric platform for data valuation and monetization is pleased to announce a major operational milestone, passing 1,000,000 transactions and USD$380 million in payment transaction volume using FinWise Bank's payment rails. The platform has processed more than $3 billion in payments for nearly 300,000 users through automated cash flow and loan management. Since March 2024, these transactions have leveraged FinWise Bank's payment services, including multiple cost-efficient payment rails. FUTR also maintains monthly deposits at FinWise from transiting payments as part of the overall relationship. As FUTR expands into new consumer markets and introduces the AI Agent App, it expects significant growth in transaction volume, processed dollars, and deposits on its banking partner platforms. With new partners and a deepening of the FinWise partnership, FUTR also anticipates greater payment automation. Leveraging FinWise's efficient and cost-effective platform, FUTR earns convenience fees on transactions and basis points on transiting deposits. 'This milestone demonstrates consumers' strong trust in FUTR to deliver real savings and convenience with our automated cash management platform coupled with smart payment rails,' said Mindy Bruns, Chief Business Officer at FUTR. 'A major part of this value is access to solid infrastructure from FinWise. We're preparing for substantial growth in users and features in the months ahead.' 'We appreciate that FUTR recognizes our vision and the value of our payments platforms,' stated Robert Keil, SVP and Chief Fintech Officer at FinWise Bank. 'We are pleased with the customer migration and see a lot of value in FUTR's consumer-focused services. This partnership with FUTR also gives FinWise the opportunity to generate lower-cost deposits.' About The FUTR Corporation FUTR's AI Agent App is focused on putting money back in consumer's wallets through a unique data monetization rewards system, personalized offers as well as agent-driven smart payment management. The FUTR AI Agent App will allow Enterprises to get rewarded for contributing consented Consumer data to the Agent and allow Brands to leverage this data to improve personalization and customer acquisition. About FinWise Bank Corp. FinWise provides Banking and Payments solutions to fintech brands. Its existing Strategic Program Lending business, conducted through scalable API-driven infrastructure, powers deposit, lending and payments programs for leading fintech brands. As part of Strategic Program Lending, FinWise also provides a Credit Enhanced Balance Sheet Program, which addresses the challenges that lending and card programs face diversifying their funding sources and managing capital efficiency. In addition, FinWise manages other Lending programs such as SBA 7(a), Owner Occupied Commercial Real Estate, and Leasing, which provide flexibility for disciplined balance sheet growth. The Company is also expanding and diversifying its business model by incorporating Payments (MoneyRails ™) and BIN Sponsorship offerings. Through its compliance oversight and risk management-first culture, the Company is well positioned to guide fintechs through a rigorous process to facilitate regulatory compliance. Forward-Looking Statements This news release may contain forward-looking statements (within the meaning of applicable securities laws) which reflect the Company's current expectations regarding future events. Forward-looking statements are identified by words such as 'believe', 'anticipate', 'project', 'expect', 'intend', 'plan', 'will', 'may', 'estimate' and other similar expressions. These statements are based on the Company's expectations, estimates, forecasts, and projections and include, without limitation, statements regarding the future success of the Company's business. The forward-looking statements in this news release are based on certain assumptions. The forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. A number of factors could cause actual results to differ materially from the results discussed in the forward-looking statements. Readers, therefore, should not place undue reliance on any such forward-looking statements. Further, these forward-looking statements are made as of the date of this news release and, except as expressly required by applicable law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Associated Press
20 hours ago
- Associated Press
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ('Lobe Sciences' or the 'Company') (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, announces the closing of the non-brokered private placement (the 'Offering') of up to 8,535,625 common share of the Company (each, a 'Share') at a price of $0.04 per Share for gross proceeds of up to $341,425 CAD. This offering was previously announced on July 29th. Securities to be issued pursuant to the Offering will be subject to a statutory four-month and one day hold period. None of the securities sold under the Offering have been and will not be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. About Lobe Sciences Ltd. Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) is a growth-stage biopharmaceutical company developing advanced treatments for rare and neurologically underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and majority-owned Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based delivery platform for the treatment of Sickle Cell Disease and a proprietary oral analog of psilocin-Conjugated Psilocin™-targeted for Chronic Cluster Headache and related disorders. The Company's mission is to improve patient outcomes through innovation and precision-driven science. For further information, please contact: Dr. Fred D. Sancilio, CEO Lobe Sciences Ltd. Investor and Media [email protected] Phone: +1 (949) 505-5623 Website: Neither the 'CSE' Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding 'Forward-Looking' Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the expectation that the Company will receive all necessary approvals to complete the Offering; the expectation that the Company will complete the Offering on the terms disclosed; and the intended use of proceeds of the Offering are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as 'intends' or 'anticipates', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'should' or 'would' or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company will receive all necessary approvals to complete the Offering; that the Company will complete the Offering on the terms and timing anticipated; and that the proceeds from the Offering will be used as anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company will not receive the necessary approvals to complete the Offering; that the Company will not complete the Offering on the terms disclosed, or at all; and that the Company will be unable to use the proceeds received from the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. SOURCE: Lobe Sciences Ltd. press release
Yahoo
a day ago
- Yahoo
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information
Conference Call Scheduled for Friday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2026 ended June 30, 2025 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2025, were $40.2 million, an increase of $21.4 million or approximately 114% as compared to the comparable period of the prior fiscal year. Operating profits were $21.7 million, an increase of $17.8 million or approximately 462%, as compared to the comparable period of the prior fiscal year. The increase in operating profits was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the comparable period of the prior fiscal year, as well as overall strong growth in the Elite label product lines as compared to the comparable period in the prior fiscal year. Conference Call Information Elite's management will host a conference call to discuss the First Quarter of Fiscal Year 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call. Date: August 15, 2025 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic)1-973-528-0008 (international) Conference number: 98840 Questions: dianne@ Financial questions by 7:00 PM EDT on Thursday, August 14, 2025 Audio Replay: The financial statements can be viewed for Elite's First Quarter of Fiscal Year 2026 on Form 10-Q here. About Elite Pharmaceuticals, Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationally under the Elite Laboratories, Inc. label. Elite also has products licensed to TAGI Pharma. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Contact:For Elite Pharmaceuticals, Will, Investor Relations, 518-398-6222Dianne@ To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
